Fox Chase Cancer Center News

PHILADELPHIA (February 1, 2022)—In a recent study, researchers at Fox Chase Cancer Center found that gene therapy using a genetically engineered viral vector was highly effective in treating cystathionine β-synthase deficiency (CBS) in mice.

PHILADELPHIA (January 31, 2022)—Margaret von Mehren, MD, chief of the Division of Sarcoma Medical Oncology at Fox Chase Cancer Center, was recently appointed the new vice chair of the Department of Hematology/Oncology.

PHILADELPHIA (January 31, 2022)—Iberia Romina Sosa, MD, PhD, an associate professor at Fox Chase Cancer Center, was recently appointed the new chief of the Division of Hematology in the Department of Hematology/Oncology.

PHILADELPHIA (January 27, 2022)—Laura Bukavina, MD, MPH, a Urologic Oncology Fellow at Fox Chase Cancer Center, has been awarded the American Society of Clinical Oncology (ASCO) Genitourinary Conquer Cancer Merit Award. She will present the winning abstract, which characterizes the gut microbiome of bladder cancer patients, at the 2022 ASCO Genitourinary Cancers Symposium in San Francisco, which is being held February 17-19.

PHILADELPHIA (January 26, 2022)—Linda Fleisher, PhD, MPH, an associate research professor in the Cancer Prevention and Control research program at Fox Chase Cancer Center, was recently appointed co-chair of the American Cancer Society’s (ACS) National Navigation Roundtable (NNRT).

PHILADELPHIA (January 24, 2022)—The two leaders of the Immersion Science Program (ISP) at Fox Chase Cancer Center, which allows students to explore science in a hands-on way while also providing valuable data that can help working researchers, have received the prestigious Elizabeth W. Jones Award for Excellence in Education from the Genetics Society of America (GSA).

PHILADELPHIA (January 20, 2022)—Researchers at Fox Chase Cancer Center have found that disparities in the incidence of head and neck cancer (HNC) are driven by behavioral and environmental risk factors rather than race. They demonstrated this in the first-ever study to compare HNC incidence in Black patients in the United States, the Caribbean, and Africa.

PHILADELPHIA (January 20, 2022)—Camille Ragin, PhD, MPH, a professor in the Cancer Prevention and Control research program at Fox Chase Cancer Center, is a member of a team that was recently awarded a grant as part of an international effort to decode Black genomes and investigate what drives breast, ovarian, and prostate cancer